Tefik Islami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tefik Islami has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Maria Antonietta Grignano
Unit of Nephrology, Dialysis and Transplantation, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
6 shared publications - Marilena Gregorini
Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy
6 shared publications - Teresa Rampino
Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy
6 shared publications - Eleonora Francesca Pattonieri
Unit of Nephrology, Dialysis and Transplantation, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
5 shared publications - Emma Diletta Stea
Unit of Nephrology, Dialysis and Transplantation, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
4 shared publications - Alessandro Tragni
Unit of Nephrology, Dialysis and Transplantation, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
2 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (4) , 66
Thrombotic Microangiopathy Following Fluoroquinolone Exposure: Two Clinical Cases
Drug-induced thrombotic microangiopathy (DiTMA) is a rare but potentially life-threatening condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ injury, most frequently involving the kidney. Diagnosis remains challenging due to nonspecific clinical features and the lack of disease-specific biomarkers. Fluoroquinolones are widely prescribed antibiotics, yet their association with DiTMA is underrecognized. We report two cases of thrombotic microangiopathy (TMA) following fluoroquinolone exposure. A comprehensive diagnostic work-up was performed to exclude primary TMA, infection-related causes, malignancy-associated TMA, and complement-mediated forms. A kidney transplant recipient developed hemolytic anemia and severe thrombocytopenia after levofloxacin exposure without kidney involvement, while a second patient developed severe acute kidney injury requiring kidney replacement therapy following ciprofloxacin treatment. ADAMTS13 activity was normal in both cases, and complement-mediated TMA was subsequently investigated. A heterozygous CFHR3-CFHR1 deletion was identified in the first case, although its significance in this setting remains uncertain. Drug causality was assessed using the Naranjo Adverse Drug Reaction Probability Scale, World Health Organization–Uppsala Monitoring Centre criteria, and the DiTMA score. Fluoroquinolones were discontinued, and supportive treatment was provided, followed by clinical and laboratory recovery without recurrence during follow-up. These cases illustrate heterogeneous TMA phenotypes following fluoroquinolone exposure but do not establish drug causality. Fluoroquinolones should be considered among potential triggers when the temporal relationship is compatible, while competing causes are carefully assessed.
- 8 October 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (4) , 66
Open AccessThrombotic Microangiopathy Following Fluoroquinolone Exposure: Two Clinical Cases
Drug-induced thrombotic microangiopathy (DiTMA) is a rare but potentially life-threatening condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ injury, most frequently involving the kidney. Diagnosis remains challenging due to nonspecific clinical features and the lack of disease-specific biomarkers. Fluoroquinolones are widely prescribed antibiotics, yet their association with DiTMA is underrecognized. We report two cases of thrombotic microangiopathy (TMA) following fluoroquinolone exposure. A comprehensive diagnostic work-up was performed to exclude primary TMA, infection-related causes, malignancy-associated TMA, and complement-mediated forms. A kidney transplant recipient developed hemolytic anemia and severe thrombocytopenia after levofloxacin exposure without kidney involvement, while a second patient developed severe acute kidney injury requiring kidney replacement therapy following ciprofloxacin treatment. ADAMTS13 activity was normal in both cases, and complement-mediated TMA was subsequently investigated. A heterozygous CFHR3-CFHR1 deletion was identified in the first case, although its significance in this setting remains uncertain. Drug causality was assessed using the Naranjo Adverse Drug Reaction Probability Scale, World Health Organization–Uppsala Monitoring Centre criteria, and the DiTMA score. Fluoroquinolones were discontinued, and supportive treatment was provided, followed by clinical and laboratory recovery without recurrence during follow-up. These cases illustrate heterogeneous TMA phenotypes following fluoroquinolone exposure but do not establish drug causality. Fluoroquinolones should be considered among potential triggers when the temporal relationship is compatible, while competing causes are carefully assessed.
- 18 February 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 148, 106765
MBL2 deficiency and IgA Nephropathy in transplant patients: Is complement inhibition always beneficial?
- 18 February 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 148, 106765
MBL2 deficiency and IgA Nephropathy in transplant patients: Is complement inhibition always beneficial?
- Open Access
- 31 December 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (1) , 32
Cutaneous Alternariosis Caused by Alternaria infectoria: A Case Report in Kidney Transplant Recipient and Literature Review
Cutaneous infections caused by dematiaceous fungi are rare in the general population but are increasingly recognized in solid organ transplant recipients as a consequence of prolonged immunosuppression. When Alternaria species are confirmed as the causative agents of a skin infection, the condition is referred to as alternariosis. These infections may clinically resemble bacterial or neoplastic lesions and require accurate diagnosis and individualized therapy. We report one case of cutaneous alternariosis in a kidney transplant recipient receiving tacrolimus-based immunosuppression. The patient was a 47-year-old woman who sustained minor trauma to her knee three months after transplantation. She developed an ulcerated, crusted lesion, which coincided with severe neutropenia. Histology, culture and molecular identification confirmed A. infectoria. Treatment included systemic azole therapy (voriconazole followed by isavuconazole) and surgical excision, resulting in resolution without recurrence. This case highlights the importance of early recognition of alternariosis in transplant recipients. Successful management typically requires combined surgical and systemic antifungal therapy, with careful monitoring of drug interactions and immunosuppressive levels to prevent toxicity or rejection.
- 31 December 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (1) , 32
Open AccessCutaneous Alternariosis Caused by Alternaria infectoria: A Case Report in Kidney Transplant Recipient and Literature Review
Cutaneous infections caused by dematiaceous fungi are rare in the general population but are increasingly recognized in solid organ transplant recipients as a consequence of prolonged immunosuppression. When Alternaria species are confirmed as the causative agents of a skin infection, the condition is referred to as alternariosis. These infections may clinically resemble bacterial or neoplastic lesions and require accurate diagnosis and individualized therapy. We report one case of cutaneous alternariosis in a kidney transplant recipient receiving tacrolimus-based immunosuppression. The patient was a 47-year-old woman who sustained minor trauma to her knee three months after transplantation. She developed an ulcerated, crusted lesion, which coincided with severe neutropenia. Histology, culture and molecular identification confirmed A. infectoria. Treatment included systemic azole therapy (voriconazole followed by isavuconazole) and surgical excision, resulting in resolution without recurrence. This case highlights the importance of early recognition of alternariosis in transplant recipients. Successful management typically requires combined surgical and systemic antifungal therapy, with careful monitoring of drug interactions and immunosuppressive levels to prevent toxicity or rejection.
- Open Access
- 13 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 8937
A Pre-Clinical Study on the Use of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor PEP 2-8 to Mitigate Ischemic Injury in a Rat Marginal Donor Model
Proprotein Convertase Subtilisin/Kexin type 9 PCSK9 inhibitors (PCSK9i) are a novel class of cholesterol-lowering agents that also offer protection against tissue ischemia by reducing apoptosis, pyroptosis, and myocardial infarct size. This study evaluated the effects of the PCSK9 inhibitor PEP 2-8 during hypothermic perfusion (HP) in a rat model of donation after circulatory death (DCD) kidney transplantation. DCD kidneys were perfused at 4 °C for six hours with either Perf-Gen solution alone (control) or Perf-Gen supplemented with PEP 2-8. Glucose and lactate dehydrogenase (LDH) levels were measured at baseline and after six hours (T6h). At T6h, kidneys were evaluated for ischemic injury, tubular cell proliferation, apoptosis, nitrotyrosine (N-Tyr) staining, tissue ATP and LDH levels, and gene expression of PCSK9 and NOX4. Metabolomic profiling was also performed. PEP 2-8 treatment significantly reduced PCSK9 expression, decreased tubular ischemic injury and necrosis, and lowered LDH release. Treated kidneys showed enhanced tubular cell proliferation, reduced apoptosis, and diminished oxidative stress, indicated by decreased N-Tyr staining and NOX4 expression. Energy metabolism was improved, with higher tissue ATP and glucose levels observed in the PEP 2-8 group. Metabolomic analysis further supported the antioxidant effects of PEP 2-8. This is the first study to demonstrate that PEP 2-8 administered during pre-transplant hypothermic perfusion provides renal protection by improving energy metabolism and reducing oxidative stress in the context of ischemic injury.
- 13 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 8937
Open AccessA Pre-Clinical Study on the Use of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor PEP 2-8 to Mitigate Ischemic Injury in a Rat Marginal Donor Model
Proprotein Convertase Subtilisin/Kexin type 9 PCSK9 inhibitors (PCSK9i) are a novel class of cholesterol-lowering agents that also offer protection against tissue ischemia by reducing apoptosis, pyroptosis, and myocardial infarct size. This study evaluated the effects of the PCSK9 inhibitor PEP 2-8 during hypothermic perfusion (HP) in a rat model of donation after circulatory death (DCD) kidney transplantation. DCD kidneys were perfused at 4 °C for six hours with either Perf-Gen solution alone (control) or Perf-Gen supplemented with PEP 2-8. Glucose and lactate dehydrogenase (LDH) levels were measured at baseline and after six hours (T6h). At T6h, kidneys were evaluated for ischemic injury, tubular cell proliferation, apoptosis, nitrotyrosine (N-Tyr) staining, tissue ATP and LDH levels, and gene expression of PCSK9 and NOX4. Metabolomic profiling was also performed. PEP 2-8 treatment significantly reduced PCSK9 expression, decreased tubular ischemic injury and necrosis, and lowered LDH release. Treated kidneys showed enhanced tubular cell proliferation, reduced apoptosis, and diminished oxidative stress, indicated by decreased N-Tyr staining and NOX4 expression. Energy metabolism was improved, with higher tissue ATP and glucose levels observed in the PEP 2-8 group. Metabolomic analysis further supported the antioxidant effects of PEP 2-8. This is the first study to demonstrate that PEP 2-8 administered during pre-transplant hypothermic perfusion provides renal protection by improving energy metabolism and reducing oxidative stress in the context of ischemic injury.
- Open Access
- 5 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3424
Engineered ATP-Loaded Extracellular Vesicles Derived from Mesenchymal Stromal Cells: A Novel Strategy to Counteract Cell ATP Depletion in an In Vitro Model
The use of adenosine triphosphate (ATP) has shown promising effects in alleviating ischemic damage across various tissues. However, the penetration of ATP into kidney tubular cells presents a challenge due to their unique anatomical and physiological properties. In this study, we introduce a novel bioinspired drug delivery system utilizing extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) and engineered to carry ATP. ATP-loaded liposomes (ATP-LPs) and ATP-loaded EVs (ATP-EVs) were prepared using microfluidic technology, followed by characterization of their morphology (DLS, NTA, SEM, TEM), ATP content, and release rate at 37 °C (pH 7.4). Additionally, the delivery efficacy of ATP-LPs and ATP-EVs was evaluated in vitro on renal cells (HK2 cells) under chemically induced ischemia. The results indicated successful ATP enrichment in EVs, with ATP-EVs showing no significant changes in morphology or size compared to naïve EVs. Notably, ATP-EVs demonstrated superior ATP retention compared to ATP-LPs, protecting the ATP from degradation in the extracellular environment. In an ATP-depleted HK2 cell model, only ATP-EVs effectively restored ATP levels, preserving cell viability and reducing apoptotic gene expression (BCL2-BAX). This study is the first to successfully demonstrate the direct delivery of ATP into renal tubular cells in vitro using EVs as carriers.
- 5 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3424
Open AccessEngineered ATP-Loaded Extracellular Vesicles Derived from Mesenchymal Stromal Cells: A Novel Strategy to Counteract Cell ATP Depletion in an In Vitro Model
The use of adenosine triphosphate (ATP) has shown promising effects in alleviating ischemic damage across various tissues. However, the penetration of ATP into kidney tubular cells presents a challenge due to their unique anatomical and physiological properties. In this study, we introduce a novel bioinspired drug delivery system utilizing extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) and engineered to carry ATP. ATP-loaded liposomes (ATP-LPs) and ATP-loaded EVs (ATP-EVs) were prepared using microfluidic technology, followed by characterization of their morphology (DLS, NTA, SEM, TEM), ATP content, and release rate at 37 °C (pH 7.4). Additionally, the delivery efficacy of ATP-LPs and ATP-EVs was evaluated in vitro on renal cells (HK2 cells) under chemically induced ischemia. The results indicated successful ATP enrichment in EVs, with ATP-EVs showing no significant changes in morphology or size compared to naïve EVs. Notably, ATP-EVs demonstrated superior ATP retention compared to ATP-LPs, protecting the ATP from degradation in the extracellular environment. In an ATP-depleted HK2 cell model, only ATP-EVs effectively restored ATP levels, preserving cell viability and reducing apoptotic gene expression (BCL2-BAX). This study is the first to successfully demonstrate the direct delivery of ATP into renal tubular cells in vitro using EVs as carriers.
- Open Access
- 11 February 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 17 (1) , 14
Atypical Hemolytic Uremic Syndrome Associated with BNT162b2 mRNA COVID-19 Vaccine in a Kidney Transplant Recipient: A Case Report and Literature Review
Case Report: We report a case of a 37-year-old female with kidney transplant, who was admitted at our hospital due to worsening renal function, nephrotic proteinuria, and anemia developed 21 days after the second dose of BNT162b2 COVID-19 vaccine (Pfizer-BioNTech). Laboratory tests revealed hemolytic anemia, thrombocytopenia, and acute kidney injury. Given the clinical picture of Thrombotic Micro-angiopathy (TMA) and severe renal impairment, plasma exchange (PEX) and dialysis were immediately started. Laboratory workup showed low C3 and C4 levels, normal activity of ADAMTS13, and the absence of anti-factor H antibodies. Molecular biology investigations revealed a heterozygous variant in exon 22 (SCR20) of the CFH gene (c.3628C>T; p.Arg1210Cys) described as an atypical Hemolytic Uremic Syndrome (aHUS) causative mutation. Our patient completed two sessions of PEX followed by eculizumab treatment with hematological improvement but no recovery of renal function. This is the first reported case of aHUS triggered by SARS-CoV-2 vaccination in a kidney transplant patient without recovery of renal function. Conclusion: Although rare, clinicians should be aware of possible nephrological complications that may appear after vaccination.
- 11 February 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 17 (1) , 14
Open AccessAtypical Hemolytic Uremic Syndrome Associated with BNT162b2 mRNA COVID-19 Vaccine in a Kidney Transplant Recipient: A Case Report and Literature Review
Case Report: We report a case of a 37-year-old female with kidney transplant, who was admitted at our hospital due to worsening renal function, nephrotic proteinuria, and anemia developed 21 days after the second dose of BNT162b2 COVID-19 vaccine (Pfizer-BioNTech). Laboratory tests revealed hemolytic anemia, thrombocytopenia, and acute kidney injury. Given the clinical picture of Thrombotic Micro-angiopathy (TMA) and severe renal impairment, plasma exchange (PEX) and dialysis were immediately started. Laboratory workup showed low C3 and C4 levels, normal activity of ADAMTS13, and the absence of anti-factor H antibodies. Molecular biology investigations revealed a heterozygous variant in exon 22 (SCR20) of the CFH gene (c.3628C>T; p.Arg1210Cys) described as an atypical Hemolytic Uremic Syndrome (aHUS) causative mutation. Our patient completed two sessions of PEX followed by eculizumab treatment with hematological improvement but no recovery of renal function. This is the first reported case of aHUS triggered by SARS-CoV-2 vaccination in a kidney transplant patient without recovery of renal function. Conclusion: Although rare, clinicians should be aware of possible nephrological complications that may appear after vaccination.